These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37240284)

  • 1. Multi-Gene Next-Generation Sequencing Panel for Analysis of
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
    Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
    Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
    Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.
    Huang CC; Tsai YF; Liu CY; Lien PJ; Lin YS; Chao TC; Feng CJ; Chen YJ; Lai JI; Phan NN; Hsu CY; Chiu JH; Tseng LM
    Ann Surg Oncol; 2022 Jun; 29(6):3578-3590. PubMed ID: 35226219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Activity of PARP Inhibitors in
    Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
    Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
    Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
    Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
    Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
    Chi KN; Barnicle A; Sibilla C; Lai Z; Corcoran C; Barrett JC; Adelman CA; Qiu P; Easter A; Dearden S; Oxnard GR; Agarwal N; Azad A; de Bono J; Mateo J; Olmos D; Thiery-Vuillemin A; Harrington EA
    Clin Cancer Res; 2023 Jan; 29(1):81-91. PubMed ID: 36043882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.